NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 258,100 shares, a decline of 32.6% from the October 31st total of 383,000 shares. Currently, 1.8% of the shares of the company are short sold. Based on an average daily volume of 237,200 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Stock Performance

NASDAQ NRSN traded up $0.05 during trading on Friday, reaching $0.98. The company’s stock had a trading volume of 323,423 shares, compared to its average volume of 144,181. NeuroSense Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.33. The business’s fifty day moving average price is $1.17 and its 200-day moving average price is $1.04. The firm has a market cap of $13.40 million, a price-to-earnings ratio of -1.15 and a beta of 1.58.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.